CIM
BIIB icon

Cambria Investment Management’s Biogen BIIB Stock Holding History

Cambria Investment Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-11,772
Closed -$2.82M – 279
2021
Q4 		$2.82M Buy
11,772
+1,199
+11% +$308K 0.47% 103
2021
Q3 		$2.99M Sell
10,573
-436
-4% -$143K 0.55% 53
2021
Q2 		$3.81M Buy
11,009
+1,526
+16% +$462K 0.65% 39
2021
Q1 		$2.65M Buy
9,483
+6,967
+277% +$1.88M 0.53% 49
2020
Q4 		$616K Sell
2,516
-136
-5% -$35.1K 0.21% 132
2020
Q3 		$752K Sell
2,652
-171
-6% -$47.7K 0.28% 72
2020
Q2 		$755K Sell
2,823
-562
-17% -$169K 0.28% 62
2020
Q1 		$1.07M Sell
3,385
-491
-13% -$149K 0.4% 41
2019
Q4 		$1.15M Buy
+3,876
New +$1.08M 0.3% 93

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Cambria Investment Management's BIIB Position: Q1 2022 in Review

Cambria Investment Management sold out of Biogen (BIIB) in Q1 2022, closing a stake of 11,772 shares — an estimated $2.82M sold.

Cambria Investment Management first reported a position in BIIB in Q4 2019 and held it in 9 quarters. The position peaked at $3.81M in Q2 2021. 951 funds tracked by Wall St. Rank hold BIIB as of Q1 2022.

  • Cambria Investment Management reported no remaining Biogen position as of Q1 2022 after selling out during the quarter.
  • Cambria Investment Management sold 11,772 Biogen shares in Q1 2022, an estimated $2.82M.
  • Cambria Investment Management first reported a position in Biogen in Q4 2019 and held it in 9 quarters.
  • Cambria Investment Management's Biogen position peaked at $3.81M in Q2 2021.
  • 951 funds tracked by Wall St. Rank held Biogen as of Q1 2022.

Based on Cambria Investment Management's 13F filing for Q1 2022, filed 16 May 2022.